AlphaCore Capital’s iShares US Pharmaceuticals ETF IHE Stock Holding History

AlphaCore Capital’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$128K	Sell	1,290 -1,800	-58%	-$162K	﹤0.01%	1185
2026 Q1	$268K	Hold	3,090	–	–	0.01%	731
2025 Q4	$262K	Buy	+3,090	New	+$247K	0.01%	863
2025 Q2	–	Sell	-13	Closed	-$917	–	1071
2025 Q1	$917	Buy	+13	New	+$903	﹤0.01%	760
2024 Q1	–	Sell	-900	Closed	-$55.6K	–	254
2023 Q4	$55.6K	Hold	900	–	–	0.01%	274
2023 Q3	$53.4K	Hold	900	–	–	0.01%	268
2023 Q2	$53.7K	Buy	+900	New	+$53.5K	0.01%	243

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

AlphaCore Capital's IHE Position: Q2 2026 in Review

AlphaCore Capital reduced its iShares US Pharmaceuticals ETF (IHE) stake by 58% in Q2 2026, selling an estimated $162K and leaving 1,290 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

AlphaCore Capital first reported a position in IHE in Q2 2023 and has held it in 7 quarters since. The position peaked at $268K in Q1 2026. 210 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

AlphaCore Capital held 1,290 shares of iShares US Pharmaceuticals ETF worth $128K as of Q2 2026.
AlphaCore Capital sold 1,800 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $162K.
iShares US Pharmaceuticals ETF made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1185 holding.
AlphaCore Capital first reported a position in iShares US Pharmaceuticals ETF in Q2 2023 and has held it in 7 quarters since.
AlphaCore Capital's iShares US Pharmaceuticals ETF position peaked at $268K in Q1 2026.
210 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.